Come and join us across the globe
Basel, Switzerland – June 2025 – The University Hospital Basel, under the direction of Prof. Dr. Marios‑Nikos Psychogios, has officially launched the ICARUS study (“IntraCranial Atherosclerosis‑Related Large‑Vessel Occlusion Treated with Urgent Stenting”), with the first patient successfully enrolled in April 2025.
Acandis GmbH (Pforzheim, Germany) is proud to be listed as a collaborator in this important investigator-initiated study, alongside the Swiss National Science Foundation. “As a company committed to advancing neurovascular care, we support important investigator-initiated studies like ICARUS,” says Dr. Andreas Schüßler, CEO of Acandis. “With our CREDO® heal stent and NeuroSpeed® PTA balloon catheter, we are proud to contribute technologies that meet the procedural demands of ICAD-related interventions. This study has the potential to help establish new treatment guidelines—offering more patients access to life-saving therapies.”
The ICARUS trial addresses a significant unmet need in acute stroke treatment. To date, no clear guideline recommendations exist for the use of urgent intracranial stenting in patients with large vessel occlusion (LVO) caused by intracranial atherosclerotic disease (ICAD) who do not achieve recanalization after standard endovascular therapy (EVT). As a result, treatment decisions in this high-risk patient group are often based on clinical experience rather than robust data.
This randomized, controlled, international multicenter study compares two approaches: early intracranial stenting versus continued conventional EVT (e.g., stent retrievers or aspiration). The trial is set to include 498 adult patients across several European centers. It will assess functional outcomes and safety endpoints to provide much-needed clinical evidence for this complex therapeutic setting.
The trial is registered under ClinicalTrials.gov Identifier NCT06472336. Further patient recruitment is ongoing, with additional participating centers expected to open in the coming months.
Complementing the aims of the ICARUS trial, Acandis is also sponsoring the RECHRUT study (ClinicalTrials.gov NCT05345483), officially titled “Rescue Stenting with CREDO® heal for Recanalisation after Unsuccessful Thrombectomy.” Led by principal investigator Dr. Hannes Nordmeyer at Städtisches Klinikum Solingen, this prospective, multicenter, observational study—initiated in January 2023—evaluates the use of the CREDO® heal stent and NeuroSpeed® balloon in ICAD-related LVO patients following unsuccessful thrombectomy.
Fig. 1: CREDO® heal stent and NeuroSpeed® PTA balloon catheter
Image © Acandis GmbH, 2025. All rights reserved
Acandis GmbH, headquartered in Pforzheim, Germany, develops and manufactures medical devices for the treatment of neurovascular diseases. The company focuses on advancing minimally invasive technologies that improve outcomes for patients suffering from complex cerebrovascular conditions.
Acandis GmbH
Theodor-Fahrner-Straße 6
75177 Pforzheim, Germany
Phone: +49 7231 155 00 0
Email:
[email protected]
Web:
www.acandis.com
